Teleflex Incorporated (TFX) Scheduled to Post Quarterly Earnings on Thursday
Teleflex Incorporated (NYSE:TFX) is set to announce its earnings results before the market opens on Thursday, November 2nd. Analysts expect the company to announce earnings of $2.00 per share for the quarter. Teleflex has set its FY17 guidance at $8.20-8.35 EPS.
Teleflex (NYSE:TFX) last released its quarterly earnings results on Thursday, August 3rd. The medical technology company reported $2.04 EPS for the quarter, beating the Zacks’ consensus estimate of $1.91 by $0.13. Teleflex had a net margin of 12.36% and a return on equity of 16.12%. The company had revenue of $528.60 million for the quarter, compared to analyst estimates of $518.98 million. During the same quarter last year, the firm posted $1.89 earnings per share. The company’s quarterly revenue was up 11.6% compared to the same quarter last year. On average, analysts expect Teleflex to post $8.29 EPS for the current fiscal year and $9.62 EPS for the next fiscal year.
Teleflex Incorporated (NYSE TFX) opened at 242.43 on Thursday. The company has a market cap of $10.92 billion, a price-to-earnings ratio of 46.36 and a beta of 1.07. The company’s 50-day moving average is $239.52 and its 200-day moving average is $213.89. Teleflex Incorporated has a 12 month low of $136.53 and a 12 month high of $248.68.
In other Teleflex news, Director Stephen K. M.D. Klasko sold 200 shares of the stock in a transaction on Friday, September 1st. The stock was sold at an average price of $211.75, for a total transaction of $42,350.00. Following the transaction, the director now owns 8,080 shares in the company, valued at approximately $1,710,940. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. In the last 90 days, insiders sold 600 shares of company stock worth $132,408. 2.39% of the stock is owned by company insiders.
A number of research firms recently weighed in on TFX. Needham & Company LLC increased their price target on Teleflex from $228.00 to $237.00 and gave the company a “buy” rating in a research note on Tuesday, September 5th. Morgan Stanley upgraded Teleflex from an “equal weight” rating to an “overweight” rating and increased their price target for the company from $220.00 to $274.00 in a research note on Wednesday, September 6th. KeyCorp restated a “hold” rating on shares of Teleflex in a research note on Wednesday, September 6th. Jefferies Group LLC restated a “buy” rating and issued a $253.00 price target (up previously from $230.00) on shares of Teleflex in a research note on Wednesday, August 9th. Finally, Barclays PLC restated an “overweight” rating and issued a $253.00 price target (up previously from $230.00) on shares of Teleflex in a research note on Tuesday, September 12th. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating and seven have assigned a buy rating to the stock. The stock presently has an average rating of “Buy” and an average target price of $260.75.
Teleflex Company Profile
Teleflex Incorporated is a provider of medical technology products. The Company designs, develops, manufactures and supplies single-use medical devices used by hospitals and healthcare providers for diagnostic and therapeutic procedures in critical care and surgical applications. The Company operates through six segments: Vascular North America; Anesthesia North America; Surgical North America; Europe, the Middle East and Africa (EMEA); Asia, and Original Equipment Manufacturer (OEM).
Receive News & Ratings for Teleflex Incorporated Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teleflex Incorporated and related companies with MarketBeat.com's FREE daily email newsletter.